Accelerate drug discovery with comprehensive genomics solutions.
From target identification and biomarker discovery to translational research, Novogene delivers high-quality sequencing services that help pharmaceutical and biotechnology researchers uncover actionable biological insights with confidence.
NGS supports every stage of the drug development pipeline by enabling researchers to identify disease-associated variants, characterize molecular mechanisms, discover predictive biomarkers, and validate therapeutic targets.
Comprehensive genomic profiling through whole genome, whole exome, and targeted sequencing enables the identification of disease-associated variants, structural changes, and actionable pathways.
Genomic and transcriptomic sequencing reveals molecular signatures associated with disease progression, therapeutic response, and treatment resistance.
Integrated transcriptomic and epigenomic analyses provide insights into gene regulation, signaling pathways, and biological responses to candidate therapeutics.
Multi-omics sequencing supports biomarker validation, translational studies, and the identification of clinically relevant molecular signatures.
Comprehensive genomic profiling supports molecular classification, patient selection, and companion diagnostic development for clinical research.
Longitudinal genomic and transcriptomic analyses reveal resistance-associated mutations, pathway adaptations, and molecular changes that inform next-generation drug development.
Accelerate drug discovery with comprehensive genomics solutions.
From target identification and biomarker discovery to translational research, Novogene delivers high-quality sequencing services that help pharmaceutical and biotechnology researchers uncover actionable biological insights with confidence.
NGS supports every stage of the drug development pipeline by enabling researchers to identify disease-associated variants, characterize molecular mechanisms, discover predictive biomarkers, and validate therapeutic targets.
Comprehensive genomic profiling through whole genome, whole exome, and targeted sequencing enables the identification of disease-associated variants, structural changes, and actionable pathways.
Genomic and transcriptomic sequencing reveals molecular signatures associated with disease progression, therapeutic response, and treatment resistance.
Integrated transcriptomic and epigenomic analyses provide insights into gene regulation, signaling pathways, and biological responses to candidate therapeutics.
Multi-omics sequencing supports biomarker validation, translational studies, and the identification of clinically relevant molecular signatures.
Comprehensive genomic profiling supports molecular classification, patient selection, and companion diagnostic development for clinical research.
Longitudinal genomic and transcriptomic analyses reveal resistance-associated mutations, pathway adaptations, and molecular changes that inform next-generation drug development.
